Synergyne ART Analytics Inc. Unveils AIM: A Revolutionary AI-Driven Endometrial Receptivity Test

Synergyne ART Analytics Inc. Unveils AIM: A Revolutionary AI-Driven Endometrial Receptivity Test, Enhancing Patient Outcomes and Clinical Efficiency

TORONTO, ONTARIO, CANADA, September 24, 2025 /EINPresswire.com/ -- Synergyne ART Analytics Inc. is proud to introduce AIM, a groundbreaking advancement in noninvasive endometrial receptivity testing that leverages machine learning (ML) to create an innovative suite of artificial intelligence (AI) tools and capabilities. AIM significantly enhances clinical efficiency and improves patient outcomes, marking a technological leap that aligns with Synergyne's mission to revolutionize patient-focused fertility care.

Steve Rowley, Global Vice President of Synergyne ART Analytics Inc., shared, "The move

to an AI-assisted process has surpassed our initial goals, streamlining workflows and enabling our team to provide more timely and accurate assessments. We're excited to transition into this new phase of growth and innovation, further enhancing the care we offer fertility patients through our clinical partnerships.”

AIM: An Evolution in Endometrial Receptivity Testing
Building on the foundation laid by Synergyne’s Matris™ test, AIM represents a new era in assessing endometrial receptivity. By harnessing ML and AI, AIM automates the generation of receptivity scores from ultrasound images, drastically improving the speed, efficacy and efficiency of the analysis process., Human oversight through our team remains critical to ensure quality and consistency, particularly in these early stages of ML and AI integration. Synergyne continues its commitment to maintaining high standards throughout and after this transition.

Benefits for Fertility Patients
Through our clinical partnerships in Canada and globally, AIM supports fertility patients and their clinicians by increasing pregnancy rates (PRs), preserving embryos, and allowing for better customization of progesterone support protocols. These improvements help their clinicians develop more effective and efficient treatment plans, ultimately enhancing patient care and the opportunity for successful outcomes.

Potential Beyond Fertility Treatment
While the primary focus remains on fertility, the AI technology used in AIM holds potential for broader applications. The ability to extract meaningful data and insights from endometrial ultrasounds using AI could be a valuable research tool in other medical fields, opening the door to future innovation and continual improvements in patient-specific medical care.

Partnership and Collaboration
The development of AIM is a testament to Synergyne’s successful partnership with Cybera’s Applied Data Science Lab. This collaboration highlights the synergy between AI and medical research in creating transformative solutions for patients worldwide.
For more information on Synergyne ART Analytics Inc. and AIM(er), please visit aimfertility.com
For more information about Cybera’s Applied Data Science Lab, please visit www.cybera.ca.